I Plavec
Overview
Explore the profile of I Plavec including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
229
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Austin T, Moss K, Morel F, Plavec I
Hum Gene Ther
. 2001 Jul;
12(10):1239-49.
PMID: 11440618
One problem in hematopoietic stem cell (HSC)-based gene therapy is the low-level, and often transient, transgene expression in progeny cells in vivo. Here we have evaluated retroviral vector designs for...
2.
Berkowitz R, Ilves H, Lin W, Eckert K, Coward A, Tamaki S, et al.
J Virol
. 2001 Mar;
75(7):3371-82.
PMID: 11238863
Because lentiviruses are able to infect nondividing cells, these viruses might be utilized in gene therapy applications where the target cell does not divide. However, it has been suggested that...
3.
BERKOWITZ R, Ilves H, Plavec I, Veres G
Virology
. 2001 Jan;
279(1):116-29.
PMID: 11145895
Efficient transfer of therapeutic genes into nondividing human cells can be accomplished by inserting the genes into lentiviruses and infecting the cells with the modified viruses. The most developed lentivirus...
4.
Murray L, Travis M, Olsson K, Plavec I, Forestell S, Hanania E, et al.
Hum Gene Ther
. 2000 Oct;
11(14):2039-50.
PMID: 11020802
Absence of durable high-level expression of transgenes from Moloney murine leukemia (Mo-MuLV) retroviral vectors has been a hurdle in bringing effective gene therapy to the clinic. In this study we...
5.
Dang Q, Auten J, Plavec I
J Virol
. 2000 Feb;
74(6):2671-8.
PMID: 10684282
Moloney murine leukemia virus-based retroviral vector expression is gradually lost during prolonged in vitro culture of CEMSS T cells. However, when the human beta interferon scaffold attachment region (IFN-SAR) was...
6.
Austin T, Salimi S, Veres G, Morel F, Ilves H, Scollay R, et al.
Blood
. 2000 Jan;
95(3):829-36.
PMID: 10648393
Using a mouse bone marrow transplantation model, the authors evaluated a Moloney murine leukemia virus (MMLV)-based vector encoding 2 anti-human immunodeficiency virus genes for long-term expression in blood cells. The...
7.
Morel F, Salimi S, Markovits J, Austin T, Plavec I
Hum Gene Ther
. 1999 Dec;
10(17):2779-87.
PMID: 10584924
We have used a mouse bone marrow transplantation (BMT) model to study the safety of retrovirus-mediated transfer of anti-HIV genes (RevM10 and HIV-1 pol antisense) into hematopoietic stem/progenitor cells (HSPCs)....
8.
Auten J, Agarwal M, Chen J, Sutton R, Plavec I
Hum Gene Ther
. 1999 Jun;
10(8):1389-99.
PMID: 10365668
The scaffold attachment region of the human interferon beta gene (IFN-SAR) inserted into a retroviral vector improved transgene expression in human primary CD4+ and CD8+ T cells, and in primary...
9.
Agarwal M, Austin T, Morel F, Chen J, Bohnlein E, Plavec I
J Virol
. 1998 Apr;
72(5):3720-8.
PMID: 9557654
We have studied retroviral transgene expression in primary human lymphocytes. Our data demonstrate that transgene expression is high in activated primary CD4+ T cells but significantly decreased in mitotically quiescent...
10.
Bonyhadi M, Moss K, VOYTOVICH A, Auten J, Kalfoglou C, Plavec I, et al.
J Virol
. 1997 Jun;
71(6):4707-16.
PMID: 9151864
A key feature of the pathogenesis of human immunodeficiency virus type 1 (HIV-1) infection is the gradual loss of CD4-positive T cells. A number of gene therapy strategies have been...